Acute respiratory failure is a common complication of drug abuse. It is more likely to develop in the setting of chronic lung disease or debility in those with limited respiratory reserve. Drugs may acutely precipitate respiratory failure by compromising respiratory pump function and/or by causing pulmonary pathology. Polysubstance overdoses are common, and clinicians should anticipate complications related to multiple drugs. Impairment of respiratory pump function may develop from central nervous system (CNS) depression (suppression of the medulla oblongata, stroke or seizures) or respiratory muscle fatigue (increased respiratory workload, metabolic acidosis). Drug-related respiratory pathology may result from parenchymal (aspiration-related events, pulmonary edema, hemorrhage, pneumothorax, infectious and non-infectious pneumonitides), airway (bronchospasm and hemorrhage), or pulmonary vascular insults (endovascular infections, hemorrhage, and vasoconstrictive events). Alcohol, cocaine, amphetamines, opiates, and benzodiazepines are the most commonly abused drugs that may induce events leading to acute respiratory failure. While decontamination and aggressive supportive measures are indicated, specific therapies to correct seizures, metabolic acidosis, pneumothorax, infections, bronchospasm, and agitation should be considered. Drug-related respiratory failure when due to CNS depression alone may portend well, but in patients with drug-related significant pulmonary pathology, a protracted course of illness may be anticipated.
1. Substance Abuse and Mental Health Services Administration. Results From the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National Findings. Office of Applied Studies, NHSDA Series H-17, 2002, DHHS Publication No. SMA 02-3758. Rockville, Md: Substance Abuse and Mental Health Services Administration.
2.
2. Drug Abuse Warning Network Report. Hospital Visits and Deaths. DAWN series D-22, 2001. DHHS Publication no. SMA 03-3779.
3.
3. Crofton J, Douglas A.The structure and function of the respiratory tract. In: Crofton J, Douglas A, eds. Respiratory Diseases. 3rd ed.Boston, Mass: Blackwell Scientific; 1981:1-79.
5. Goldstein LB, Adams R, Becker K, et al.Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke.2001;32: 280-299.
6.
6. Perez JA Jr, Arsura EL, Strategos S. Methamphetamine-related stroke: four cases. J Emerg Med. 1999;17: 469-471.
7.
7. Siegel AJ, Sholar MB, Mendelson JH, et al.Cocaine-induced erythrocytosis and increase in von Willebrand factor: evidence for drug-related blood doping and prothrombotic effects. Arch Intern Med. 1999;159: 1925-1929.
8.
8. Kaku DA, Lowenstein DH.Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann Intern Med. 1990;113: 821-827.
9.
9. Levine SR, Brust JC, Futrell N, et al.Cerebrovascular complications of the use of the “crack” form of alkaloidal cocaine. N Engl J Med. 1990;323: 699-704.
13. Derlet RW, Heischober B.Methamphetamine: stimulant of the 1990s?Western J Med. 1990;153: 625-628.
14.
14. Shannon M, Quang LS.Gamma-hydroxybutyrate, gammabutyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care. 2000;16: 435-440.
17. Vianna LG, Koulouris N, Lanigan C, Moxham J.Effect of acute hypercapnia on limb muscle contractility in humans. J Appl Physiol.1990;69: 1486-1493.
18.
18. Juan G, Calverly P, Talamo C, Schnader J, Roussos C.Effect of carbon dioxide on diaphragmatic function in the human being. N Engl J Med. 1984;310: 874-879.
19.
19. Westerblad H, Lee JA, Lannergren J, Allen DG.Cellular mechanisms of fatigue in skeletal muscle. Am J Physiol. 1991;261: C195-C209.
20.
20. Burns MJ, Schwartzstein RM. Decontamination of poisoned patients. In: Rose BD, ed. UpToDate 9.2. Wellesley, Mass: UpToDate; 2001.
21.
21. Bynum LJ, Pierce AK.Pulmonary aspiration of gastric contents. Am Rev Respir Dis. 1976;114: 1129.
22.
22. James CF, Modell JH, Gibbs CP, Kuck EJ, Ruiz BC.Pulmonary aspiration: effect of volume and pH in rates. Anesth Analg. 1984;63: 655.
23.
23. Bartlett JG.Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis. 1993;4: S248-S255.
25. Lorber B, Swenson RM.Bacteriology of aspiration pneumonia: a prospective study of community and hospitalacquired cases. Ann Intern Med. 1974;81: 329-331.
26.
26. Levison ME, Mangura CT, Lorber B, et al.Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med. 1983;98: 466-471.
27.
27. Gudiol F, Manressa F, Pallares R, et al.Clindamycin vs. penicillin for anaerobic lung infections. Arch Intern Med. 1990;158: 2525.
28.
28. Eykyn SJ.The therapeutic use of metronidazole in anaerobic infection: six years’ experience in a London hospital. Surgery. 1983;93: 209-214.
29.
29. Perlino CA.Metronidazole vs. clindamycin treatment of anaerobic pulmonary infection: failure of metronidazole therapy. Arch Intern Med. 1981;141: 1424-1427.
30.
30. Muder R.Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am J Med.1998;105: 319-330.
31.
31. O’Donnell AE, Pappas LS.Pulmonary complications of intravenous drug abuse. Chest. 1988;94: 251-253.
32.
32. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342: 1301-1308.
33.
33. Brower RG, Rubenfeld GD.Lung-protective ventilation strategies in acute lung injury. Crit Care Med. 2003;31(suppl 4): S312-S316.
34.
34. Rosenow EC.The spectrum of drug-induced pulmonary disease. Ann Intern Med. 1972;77: 977.
38. Rome LA, Lippmann ML, Dalsey WC, Taggart P, Pemerantz S.Prevalence of cocaine use and its impact on asthma exacerbation in an urban population. Chest. 2000;117: 1324-1329.
39.
39. Tashkin DP.Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med. 2001;7: 43-61.
40.
40. Vally H, de Klerk N, Thompson PJ.Alcoholic drinks: important triggers for asthma. J Allergy Clin Immunol. 2000;105: 462-467.
41.
41. Osborn HH, Tang M, Bradley K, Duncan BR.New-onset bronchospasm or recrudescence of asthma associated with cocaine abuse. Acad Emerg Med. 1997;4: 689-692.
42.
42. Louria DB, Hensle T, Rose J.The major medical complications of heroin addiction. Ann Intern Med. 1967;67: 1-22.
43.
43. Lewis JW Jr, Groux N, Elliott JP Jr, Jara FM, Obeid FN, Magilligan DJ Jr.Complications of attempted central venous injections performed by drug abusers. Chest. 1980;78: 613-617.
44.
44. Aguado JM, Arjona R, Ugarte P.Septic pulmonary emboli: a rare cause of bilateral pneumothorax in drug abusers. Chest. 1990;98: 1302-1304.
46. Hojer J.Severe metabolic acidosis in the alcoholic: differential diagnosis and management. Hum Exp Toxicol. 1996;15: 482-488.
47.
47. Ayers JG, Clark TJ.Alcoholic drinks and asthma: a survey. Br J Dis Chest. 1983;77: 370-375.
48.
48. Vally, H, Carr A, El-Saleh J, Thompson P.Wine-induced asthma: a placebo controlled assessment of its pathogenesis. J Allergy Clin Immunol. 1999;103: 41-46.
49.
49. Fujimura M, Myou S, Kamio Y, et al.Increased airway responsiveness to acetaldehyde in asthmatic subjects with alcohol-induced bronchoconstriction. Eur Respir J. 1999;14: 19-22.
50.
50. Shimoda T, Kohno S, Takao A, et al.Investigation of the mechanism of alcohol-induced bronchial asthma. J Allergy Clin Immunol. 1996;97: 74-84.
51.
51. Gong H Jr, Tashkin DP, Calvarese BM.Alcohol-induced bronchospasm in an asthmatic patient: pharmacologic evaluation of the mechanism. Chest. 1981;80: 167-173.
52.
52. Takao A, Shimoda T, Kohno S, Asai S, Harda S.Correlation between alcohol-induced asthma and acetaldehyde dehydrogenase-2 genotype. J Allergy Clin Immunol. 1998;101: 576-580.
53.
53. Moss M, Guidot DM, Wong-Lambertina M, Ten Hoor T, Perez RL, Brown LA.The effects of chronic alcohol abuse on pulmonary glutathione homeostasis. Am J Respir Crit Care Med. 2000;161: 414-419.
55. Chu J, Wang RY, Hill N.Update in clinical toxicology. Am J Respir Crit Care Med. 2002;166: 9-15.
56.
56. Jacobsen D, McMartin KE.Methanol and ethylene glycol poisonings: mechanism of toxicity, clinical course, diagnosis and treatment. Med Toxicol. 1986;1: 309-334.
57.
57. Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA.American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40: 415-446.
58.
58. Jaffe J, Martin WR.Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 8th ed.Elmsford, NY: Pergamon; 1990:362-396.
59.
59. Sporer KA.Acute heroin overdose. Ann Intern Med. 1999;130: 584-590.
60.
60. Bradberry JC, Raebel MA.Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intell Clin Pharm.1981;15: 945-950.
61.
61. Wang DS, Sternbach G, Varon J.Nalmefene: a long-acting opioid antagonist—clinical applications in emergency medicine. J Emerg Med. 1998;16: 471-475.
62.
62. Jay SJ, Johanson WG, Pierce AK.Respiratory complications of overdose with sedative drugs. Am Rev Respir Dis. 1975;112: 591.
63.
63. Weinbroum AA, Flaishon R, Sorkine P, et al.A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug Saf. 1997;17: 81.
64.
64. Graudins A, Aaron CK.Sedative-hypnotic poisoning. In: Irwin RS, Cerra FB, Rippe JM, eds. Intensive Care Medicine. Philadelphia:, Pa Lipincott-Raven; 1999:1782.
65.
65. Wyse DG.Deliberate inhalation of volatile hydrocarbons: a review. Can Med Assoc J. 1973;108: 71-74.
66.
66. Gillman MA.Nitrous oxide, an opioid addictive agent: review of the evidence.Am J Med. 1986;81: 97-102.
67.
67. Linden CH.Volatile substances of abuse. Emerg Med Clin North Am. 1990;8: 559-578.
69. Stevens DC, Campbell JP, Carter JE, Watson WA.Acid-base abnormalities associated with cocaine toxicity in emergency department patients. J Toxicol Clin Toxicol. 1994;32: 31-39.
70.
70. Ettinger NA, Albin RJ.A review of the respiratory effects of smoking cocaine. Am J Med. 1989;87: 664-668.
71.
71. Osborn HH, Tang M, Bradley K, Duncan BR.New onset bronchospasm or recrudescence of asthma associated with cocaine abuse. Acad Emerg Med. 1997;4: 689-692.
72.
72. Forrester JM, Steele AW, Waldron JA, Parsons PE.Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histopathologic findings. Am Rev Respir Dis. 1990;142: 462-467.
74. Smith WS, Matthay MA.Evidence for a hydrostatic mechanism in human neurogenic pulmonary edema. Chest. 1997;111: 1326-1333.
75.
75. Kleerup EC, Wong M, Marques-Magallanes JA, Goldman MD, Tashkin DP.Acute effects of intravenous cocaine on pulmonary artery pressure and cardiac index in habitual crack smokers. Chest. 1997;111: 30-35.
76.
76. Tashkin DP, Kleerup EC, Koyal SN, Marques JA, Goldman MD.Acute effects of inhaled and i.v. cocaine on airway dynamics. Chest. 1996;110: 904-910.
77.
77. Garcia-Rostan Y, Perez GM, Garcia Bragado F, Puras Gil AM.Pulmonary hemorrhage and antiglomerular basement membrane antibody-mediated glomerulonephritis after exposure to smoked cocaine (crack): a case report and review of the literature. Pathol Int. 1997;47: 692-697.
78.
78. Tashkin DP, Gorelick D, Khalsa ME, Simmons M, Chang P.Respiratory effects of cocaine freebasing among habitual cocaine users. J Addict Dis. 1992;11: 59-70.
79.
79. Smith GT, McClaughry PL, Purkey J, Thompson W.Crack cocaine mimicking pulmonary embolism on pulmonary ventilation/perfusion lung scan: a case report. Clin Nuclear Med. 1995;20: 65-68.
80.
80. Om A.Cardiovascular complications of cocaine. Am J Med Sci. 1992;303: 333-339.
81.
81. Lewman LV.Fatal pulmonary hypertension from intravenous injection of methylphenidate (Ritalin) tablets. Hum Pathol. 1972;3: 67-70.
82.
82. Kissner DG, Lawrence WD, Selis JE, Flint A.Crack lung: pulmonary disease caused by cocaine abuse. Am Rev Respir Dis. 1987;136: 1250-1252.
83.
83. Meleca RJ, Burgio DL, Carr RM, Lolachi CM.Mucosal injuries of the upper aerodigestive tract after smoking crack or freebase cocaine. Laryngoscope. 1997;107: 620-625.
84.
84. Reino AJ, Lawson W.Upper airway distress in crackcocaine users. Otolaryngol Head Neck Surg. 1993;109: 937-940.
85.
85. Ashton CH.Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178: 101-106.
86.
86. Birrer RB.Calderon pneumothorax, pneumomediastinum, and pneumopericardium following Valsalva’s maneuver during marijuana smoking. N Y State J Med. 1984;84: 619-620.
87.
87. Szyper-Kravitz M, Lang R, Manor Y, Lahav M.Early invasive pulmonary aspergillosis in a leukemia patient linked to aspergillus contaminated marijuana smoking. Leuk Lymphoma. 2001;42: 1433-1437.
